Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphomaPublished in Current Oncology, 2017V Babashov, MA Begen, J Mangel, GS Zaric. Current Oncology, 24(1), 6–14, 2017.Download paper hereShare on Twitter Facebook LinkedIn Previous Next